Medpharm And Tergus Pharma Merge To Lead Innovation

MedPharm, a global leader in topical and transdermal CDMO services and part of the Ampersand Capital Partners portfolio, is set to merge with Tergus Pharma, backed by Great Point Partners. The merged entity will continue under the MedPharm name, creating a comprehensive CDMO with extensive expertise in scientific research, clinical trial manufacturing, and commercial production. Great Point Partners, the primary investor in Tergus, will maintain a significant minority stake in the new MedPharm, while Ampersand Capital Partners and Bourne Partners Strategic Capital will hold the majority ownership.

As a result of the merger, Michael Kane, CEO of Tergus Pharma, will take on the role of CEO at MedPharm, with Patrick Walsh remaining as Executive Chairman. The newly formed organization aims to be a leader in providing a complete range of drug development and manufacturing services to pharmaceutical innovators. The merger combines Tergus and MedPharm’s strengths, enabling seamless commercial production and serialization alongside formulation development, in vitro testing, and clinical manufacturing. Additionally, the company will expand its capabilities to include the development and production of hormone-based and highly potent drugs at its GMP manufacturing facility in Durham, NC.

Michael Kane said, "This strategic partnership is an exciting opportunity to deliver extensive pharmaceutical product development resources fueled by a robust team of scientific experts while leveraging our cutting-edge topical GMP facility to seamlessly meet our customers' commercial production needs. With locations in both the United Kingdom and the United States, we are well positioned to provide exceptional support to our existing and prospective pharmaceutical clients."

Patrick Walsh further added, "Pharma clients have been seeking a reliable, integrated service offering for their ophthalmic, topical and transdermal development and manufacturing projects. This merger creates an immediate option with two organizations already well-positioned in the industry.”